We are live on
!
Find out more
DPA
Devon Park Associates Portfolio holdings
AUM
$30.8M
1-Year Est. Return
0.85%
This Fund
S&P 500
This Quarter
Est. Return
+14.62%
1 Year Est. Return
+0.85%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$131M
AUM Growth
–
Cap. Flow
+$121M
Cap. Flow
% of AUM
92.35%
Top 10 Holdings %
Top 10 Hldgs %
100%
Holding
4
New
4
Increased
–
Reduced
–
Closed
–
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
ZSPH
ZS PHARMA INC COMS TK (DE)
ZSPH
|
+$102M |
| 2 |
TVRD
Tvardi Therapeutics
TVRD
|
+$10.3M |
| 3 |
CEMP
Cempra, Inc.
CEMP
|
+$5.83M |
| 4 |
Protara Therapeutics
TARA
|
+$3.28M |
Top Sells
No sells this quarter
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 18.33% |
Similar funds
DMS
SCM
NCA
EDRPMB
HSS
LOCC
BSCM
GPI
Devon Park Associates's Q4 2014 Portfolio in Review
Q4 2014 is the first quarter with a 13F filing on record for Devon Park Associates, which disclosed 4 positions worth $131M. Its ten largest holdings account for 100% of the portfolio.
Its largest position is ZS PHARMA INC COMS TK (DE): 2,576,723 shares worth $107M.
By sector, the portfolio is most concentrated in Healthcare at 18% of assets.
- Devon Park Associates's largest Q4 2014 buy was ZS PHARMA INC COMS TK (DE): 2,576,723 shares worth $107M.
- Devon Park Associates's ten largest holdings make up 100% of its $131M portfolio in Q4 2014.
- Devon Park Associates disclosed 4 positions in Q4 2014, its first 13F filing on record.
Based on Devon Park Associates's 13F filing for Q4 2014, filed 13 Feb 2015.